Recent research has highlighted the benefits of starting Jakafi (ruxolitinib) treatment early for patients with myelofibrosis, showing that early initiation significantly enhances spleen response rates and reduces spleen size compared to delayed treatment. This conclusion arises from a post hoc analysis of the JUMP trial, as published in Leukemia & Lymphoma.
Key Findings:
- Higher Response Rates: Patients who began Jakafi within 12 months of their myelofibrosis diagnosis had a 12-week spleen response rate of 43.6%. In contrast, those who started treatment after this period had a rate of only 34.9%. Similar advantages were observed for patients who started within 24 months (43.5%) compared to those who delayed treatment beyond this timeframe (33.1%).
- Spleen Size Reduction: The analysis also revealed that mean spleen length changes were significantly greater in patients who initiated treatment earlier. For instance, at 12 weeks, those starting within 12 months experienced a mean spleen length reduction of 58.4%, whereas those who began treatment later only saw a reduction of 49.0%. This trend continued over the study duration.
Expert Insights:
Lead author Dr. Pankit Vachhani, an associate professor at the University of Alabama at Birmingham, states, “These results support early initiation of ruxolitinib to provide patients with the best opportunity to obtain a spleen response.”
About the JUMP Trial:
The JUMP trial included 2,233 patients from various countries who did not have access to Jakafi outside of clinical settings. The study aimed to assess the safety and effectiveness of Jakafi in a real-world context, including patients with low platelet counts and those without spleen enlargement.
In addition to achieving higher spleen response rates, patients starting treatment within two years of diagnosis demonstrated enhanced health-related quality of life and better symptoms overall.
Safety and Effectiveness:
The mean starting doses of Jakafi were similar across different timing subgroups, and dose adjustments were made as necessary. Although improvements in symptom response and overall survival were consistent regardless of how soon patients began treatment, it is noted that the benefits of early intervention remain significant.
Conclusion:
This analysis reinforces prior studies that indicate the clinical advantages of earlier Jakafi treatment for individuals with myelofibrosis, particularly in achieving superior spleen responses and better overall health outcomes. For patients and healthcare providers, these findings emphasize the importance of prompt treatment initiation to optimize care and improve quality of life.
More Reading
Improved Outcomes in Myelofibrosis with Optimal Jakafi (Ruxolitinib) Dosing
Join the Conversation on CancerConnect!
Reference:
- Vachhani P, Guglielmelli P, Repp J, Hamer-Maansson JE, Braunstein E, Al-Ali HK. Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis. Leuk Lymphoma. 2025;66(5):981-984. doi:10.1080/10428194.2024.2447884
- Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020 Jun;189(5):888-903. doi:10.1111/bjh.16462
- Palandri F, Al-Ali HK, Guglielmelli P, Zuurman MW, Sarkar R, Gupta V. Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers (Basel). 2023;15(10):2859. doi:10.3390/cancers15102859
